JPRN-UMIN000007455Completed未知
Effectiveness of aripiprazole augmentation therapy in patients with bipolar depression who do not respond to mood stabilizers: A randomized, double-blind, placebo-controlled study - Effectiveness of AripipRazole THerapy in Bipolar Depression (EARTH BD)
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Kansai Medical University
- Enrollment
- 93
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18years-old to 65years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who meet DSM-IV-TR for significant Axis I and II disorders except bipolar disorder. Patients who received antipsychotics or antidepressants within 4 weeks prior to screening phase. Patients who have a ECT therapy within 3 months prior to screening phase. Patients who are comatose and strongly affected by central nervous system depressants such as barbiturates or anesthetics. Patients who have received adrenaline. Patients known to have a history or complication of allergy to aripiprazole. Patients with a history or a complication of diabetes. Women who are pregnant, possibly pregnant, or breast-feeding. Patients who have been judged by the investigator to be inappropriate for inclusion in the trial for any other reasons Patients who have a complication of serious physical disorder. Patients who have been judged by the investigators to have a high risk of suicide.
Investigators
Similar Trials
Completed
Not Applicable
Effectiveness of aripiprazole augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder with poor insightRefractory obsessive-compulsive disorderJPRN-UMIN000007069Hyogo College of Medicine116
Not yet recruiting
Not Applicable
To study therapeutic efficacy of aripiprazole augmentation in treatment resistant obsessive compulsive disorderCTRI/2021/04/032524GMC medical college
Completed
Not Applicable
Augmentation therapy with aripiprazole in selective serotonin reuptake inhibitor(SSRI)-refractory obsessive-compulsive disorder(OCD); A randomized double blind placebo controlled trialobsessive-compulsive disorderJPRN-UMIN000008743Kyushu University60
Completed
Phase 4
Aripiprazole effect in the treatment of residual symptoms in patients with schizophreniaIRCT2017013032236N3Vice chancellor for research, Mazandaran University of Medical Sciences50
Completed
Phase 2
Effect of aripiprazole on prevention of deleriumIRCT2017011810178N12Shahid Beheshti University of Medical Science40